Aegis Life and Entos Reach Important Milestone in COVID Vaccine Development
SAN DIEGO, Calif. & EDMONTON, Alberta--Aegis Life, Inc. (Aegis) along with its partner Entos Pharmaceuticals (Entos) has announced that the Phase 1 part of their clinical trial for Covigenix VAX-002, which is designed to assess a COVID-19 booster vaccine, is completely enrolled. This vaccine, Covigenix VAX-002, is uniquely crafted with the Entos Fusogenix PLV technology, utilizing plasmid DNA that produces crucial SARS-CoV-2 antigens. This cutting-edge approach aims to provide protection against the latest circulating omicron variants of the virus.
Insight into the Clinical Trial
The Phase 1/2 clinical trial for Covigenix VAX-002 is taking place across 12 locations in Canada. The main goal of the Phase 1 segment is to determine both safety and the ideal dosage of the vaccine as a booster against COVID-19. The trial is designed to include an interim analysis of the Phase 1 group, and findings from this analysis will help shape the dosing schedule for the next Phase 2 trial. The second phase is focused on evaluating the safety and immunogenicity response tied to the optimal booster dose.
Dr. Steve Chen, Aegis’s Chief Medical Officer, expressed his gratitude toward the participating sites and volunteers. He noted the excitement within the clinical community regarding Covigenix VAX-002 and its potential to produce a strong immune response against the existing SARS-CoV-2 strains. Chen stated, "Our ability to enroll the Phase 1 portion of this study in just a few weeks demonstrates the enthusiasm surrounding Covigenix VAX-002, which we believe could offer a more durable and effective vaccine booster option than those available today."
Benefits of Fusogenix Technology
Recent research confirming the safety and effectiveness of Fusogenix technology has been published in respected journals. These studies reveal how the proteolipid vehicles that make use of FAST proteins can successfully tackle the challenges faced by current viral and non-viral genetic medicine delivery methods. The benefits of the FAST-PLV system include enhanced delivery to specific tissues beyond the liver, the ability for re-dosing, and increased expression of genetic therapies across multiple tissue types.
About Aegis Life, Inc.
Aegis Life, Inc. is committed to advancing next-generation genetic vaccines and therapies that target some of the most daunting infectious diseases worldwide. By utilizing the Fusogenix PLV platform, originally developed by Entos Pharmaceuticals, Aegis Life is able to efficiently push forward the development of safe and effective RNA or DNA vaccines and therapeutics.
About Entos Pharmaceuticals Inc.
Entos Pharmaceuticals is dedicated to creating pioneering solutions in genetic medicine, focusing on the safe and effective delivery of nucleic acids. With a strong commitment to advancing next-gen genetic therapies via the Fusogenix PLV delivery system, Entos is setting the stage for transformative healthcare treatments. The company has partnered with various global organizations to broaden and enhance the reach of its innovative platform.
Frequently Asked Questions
What is Covigenix VAX-002?
Covigenix VAX-002 is a COVID-19 vaccine that is being developed as a booster, utilizing advanced DNA technology to provide protection against SARS-CoV-2.
What is the goal of the current clinical trial?
The purpose of the trial is to evaluate the safety and effectiveness of Covigenix VAX-002, as well as to determine the optimal dosage for successful vaccination.
How does Fusogenix technology provide an advantage?
This technology enhances the delivery of genetic material to various tissues and allows for potential re-dosing, thereby increasing treatment efficacy.
Who is leading the work on Covigenix VAX-002?
Aegis Life, Inc. is leading the development, in collaboration with Entos Pharmaceuticals, which specializes in innovative systems for drug delivery.
Where is the clinical trial taking place?
The Phase 1/2 clinical trial is being held at multiple sites throughout Canada.
